Ocata Therapeutics Inc fka OCAT

[lefty18]

A recap of the conference call highlights:

1. The gerentology market predicted to be a trillion dollars.

2. Regenerative medicine will constitute the lion's share of that market.

3. Advanced Cell Technology has developed a technology to propogate stem cells lines without destroying an embryo.

4. They have also created a Reduced Complexity Library (RCL) that enables them to create organs that avoid rejection, a phenomenon analogous to the universal blood type (O+).

5. Short term, this gives the company an opportunity to receive funding from the California state government project for stem cell research.

6. In the near term we may be hearing of a partnership between ACTC and a large pharmaceutical company.

My take is that ACTC is likely the front-runner in the field of regenerative medicine. If the RCL allows them to develop rejection-free organs, they will be able to capture a substantial portion of the trillion dollar gerentological market.